Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1(+) Tregs

A major complication of hemophilia A therapy is the development of alloantibodies (inhibitors) that neutralize intravenously administered coagulation factor VIII (FVIII). Immune tolerance induction therapy (ITI) by repetitive FVIII injection can eradicate inhibitors, and thereby reduce morbidity and...

Descripción completa

Detalles Bibliográficos
Autores principales: Becker-Gotot, Janine, Meissner, Mirjam, Kotov, Vadim, Jurado-Mestre, Blanca, Maione, Andrea, Pannek, Andreas, Albert, Thilo, Flores, Chrystel, Schildberg, Frank A., Gleeson, Paul A., Reipert, Birgit M., Oldenburg, Johannes, Kurts, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663153/
https://www.ncbi.nlm.nih.gov/pubmed/36107620
http://dx.doi.org/10.1172/JCI159925

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663153/
https://www.ncbi.nlm.nih.gov/pubmed/36107620
http://dx.doi.org/10.1172/JCI159925

Ejemplares similares